BTIG Maintains Buy on Glaukos, Raises Price Target to $252
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $234 to $252.
Last updated: 2026-11-18 02:03:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Glaukos Corporation (GKOS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $243.27, with a market capitalization of $14.55B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $87.32 to $255.19. This page covers its latest market performance, valuation, price trends and company information.
$14.55B | |
$242.60 | |
$247.14 | |
$239.68 | |
$244.88 | |
572.23K | |
1.18M | |
-- | |
$255.19 | |
$87.32 | |
-- | |
-- |
Glaukos Corporation (GKOS) last closed at $243.27 as of 2026-11-18 00:31:00, down 0.67% ($1.63) from the previous close of $244.88.
During the latest regular trading session, GKOS traded between $239.68 and $247.14, with a volume of 572.23K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Glaukos Corporation (GKOS) moved from $224.41 to $243.27, representing a gain of 8.40% ($18.86).
The stock traded between $219.06 and $250.61 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 862.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 92.9%
GKOS is currently trading at $243.27, placing it 92.9% of the way from its 52-week low of $87.32 to its 52-week high of $255.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 1,094 |
| Exchange | NYSE |
| Company Website |
Latest news related to Glaukos Corporation and GKOS stock.
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $234 to $252.
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
AMN Healthcare (AMN) is well-positioned for growth driven by strong healthcare staffing demand, MSP opportunities, and technology investments, with Nurse and Allied revenues rising 27% in Q3. However, the stock faces headwinds from visa delays affecting international nurse placements, pricing pressures, and weakness in Physician and Technology segments. The company holds a Zacks Rank #3 (Hold) rating despite surging 140.5% year-to-date.
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.
Eligible investors can buy real shares of Glaukos Corporation (GKOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GKOS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GKOS shares and USD.
GKOS Shares to USD
1.00 GKOS shares = 243.268 USD
Calculations are estimates based on the latest available price and are for reference only.